Advertisement
News
Subscribe to MDT Magazine News

CDRH FY 2010 Strategic Priorities - Accomplishments

December 9, 2010 7:34 am | by U.S. Food & Drug Administration | Comments

In January we released to the public and began implementing our 2010 strategic plan. The plan, CDRH FY 2010 Strategic Priorities, identified four priority areas of activity that presented significant opportunities to improve our effectiveness in...

TOPICS:

Analyzing the Unborn Genome

December 9, 2010 7:34 am | by Massachusetts Institute of Technology | Comments

Mapping the genome of a fetus from its mother's blood could mean less risky screening for prenatal diseases.

Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium

December 9, 2010 7:34 am | by Bio-Medicine.Org | Comments

BRIDGEWATER, N.J., Dec. 9, 2010 /- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) announced today that the final survival analysis (10-year follow-up) of the BCIRG001 study that included a Taxotere® (docetaxel) Injection Concentrate chemotherapy treatment regimen in the adjuvant...

TOPICS:
Advertisement

Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services

December 9, 2010 7:33 am | by Bio-Medicine.Org | Comments

ALISO VIEJO, Calif., Dec. 9, 2010 /- Ambry Genetics, a global leader in genomic services to the healthcare and life sciences industries, announced today that it has officially launched their Illumina HiSeq 2000 Next Generation Sequencing Services. Ambry Genetics has been an early adapter...

TOPICS:

Caliper Life Sciences to Acquire Cambridge Research & Instrumentation

December 9, 2010 7:33 am | by Bio-Medicine.Org | Comments

HOPKINTON and WOBURN, Mass., Dec. 9, 2010 /- Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of products and services for drug discovery research, today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research &...

TOPICS:

Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients

December 9, 2010 7:33 am | by Bio-Medicine.Org | Comments

EAST HANOVER, N.J., Dec. 9, 2010 /- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been...

TOPICS:

Anthera Announces Update Call Regarding Vial Problems

December 9, 2010 7:32 am | by Bio-Medicine.Org | Comments

HAYWARD, Calif., Dec. 9, 2010 /- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and...

TOPICS:

HeartWare plans to sell $100M in senior notes

December 9, 2010 6:45 am | by The Associated Press | Comments

Heart device maker HeartWare International Inc. said Thursday it plans to sell $100 million in senior notes due in 2016, and disclosed that its biggest shareholder is selling part of its stake in the company.The news sent shares sliding $6.04, or 6.8 percent, to $82.86 in morning...

Advertisement

Innovative Micro Technology adds to its arsenal of through-silicon via offerings

December 9, 2010 6:33 am | by I-Micronews | Comments

Innovative Micro Technology, Inc. (IMT) announced the addition of a new geometry point in its technology roadmap for Through Silicon Vias (TSVs).

MicroVision and Pioneer to jointly commercialize innovative laser display products

December 9, 2010 6:32 am | by I-Micronews | Comments

MicroVision, Inc. (NASDAQ: MVIS), a leader in innovative ultra-miniature laser display technology, announced today that it has entered into a memorandum of understanding (MOU) with Pioneer Corporation, one of the top original equipment manufacturers (OEMs) of high-performance audio, video...

Alnylam elects Fanucci to board

December 9, 2010 5:36 am | by Mass High Tech: The Journal of New England Technology | Comments

RNAi-focused therapeutics firm Alnylam Pharmaceuticals Inc. has elected Marsha H. Fanucci, former chief financial officer of fellow Cambridge-based biotechnology company Millennium Pharmaceuticals Inc., to its board of directors.

Alere gets OK for $50M stock buyback

December 9, 2010 5:35 am | by Mass High Tech: The Journal of New England Technology | Comments

The board of directors at Waltham-based Alere Inc., the healthcare management company formerly known as Inverness Medical Innovations, has given it approval of a stock repurchase program for up to $50 million worth of its common or preferred stock.

Manufacturing Growth Forecasted for 2011

December 9, 2010 5:35 am | by Material Handling Industry of America | Comments

The U.S. manufacturing sector will grow in 2011, with manufacturing revenue increasing by 5.6% according to the Institute for Supply Management (ISM) semi-annual forecast released.The overall forecast projects optimism about the U.S. economy for 2011.

VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Graft...

December 9, 2010 5:35 am | by Bio-Medicine.Org | Comments

ANN ARBOR, Mich., Dec. 9, 2010 /- Terumo Cardiovascular Systems has announced the introduction of the VirtuoSaph® Plus Endoscopic Vessel Harvesting System following clearance by the U.S. Food and Drug Administration (FDA). (Logo: http://photos.prnewswire.com/prnh/20041217/DEF008LOGO)...

TOPICS:

Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer

December 9, 2010 5:34 am | by Bio-Medicine.Org | Comments

SANTA ROSA, Calif., Dec. 9, 2010 /- Osseon Therapeutics, Inc. today named Mr. Gary Coughlen, CPA as the company's Chief Financial Officer, effective immediately. Mr. Coughlen was most recently the Chief Financial Officer of PolyRemedy, Inc., a private-equity medical device company focused...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading